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Rituximab Immunotherapy in 
Pemphigus: Therapeutic Effects 
Beyond B-Cell Depletion
Giovanna Zambruno1 and Luca Borradori2
The anti-CD20 mAb rituximab, first approved for use in B-cell malignancies, is 
increasingly used to treat a variety of autoimmune diseases. Two studies in this 
issue investigate the effects of rituximab in pemphigus. Rituximab induces not 
only a depletion of all B cells and a decline of antidesmoglein autoantibodies 
but also a decrease in desmoglein-specific T cells. Furthermore, B-cell popula-
tions recovered after treatment were modified. These novel aspects may con-
tribute to the clinical responses observed in patients.
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Rituximab is a potent B-cell-depleting 
chimeric anti-CD20 mAb first approved 
in 1997 for use in relapsed or refractory 
low-grade follicular B-cell lymphoma. 
Since then, it has become a major 
therapeutic agent in the management 
of several B-cell malignancies. In par-
allel, there has been a growing interest 
in exploiting the B-cell-depleting effect 
of rituximab in treating autoimmune 
conditions in which autoantibodies 
(autoAb) are thought to play a patho-
genetic role. The 75 trials currently list-
ed in the National Institutes of Health 
registry (http://www.clinicaltrials.gov) 
clearly illustrate the considerable activ-
ity in this field. Since 2006, rituximab 
has been approved for the treatment of 
active rheumatoid arthritis not respond-
ing to tumor necrosis factor block-
ers (Edwards and Cambridge, 2006; 
Kessel et al., 2008). Furthermore, this 
chimeric antibody has been increas-
ingly used off-label in a variety of 
autoimmune diseases, including sys-
temic lupus eryth ematosus, Sjögren’s 
syndrome, idiopathic thrombocy-
topenic purpura, acquired hemophilia, 
autoimmune hemolytic anemia, HCV 
mixed cryoglobulinemia, Wegener’s 
granulomatosis, autoantibody-associ-
ated neuropathies, myasthenia gravis, 
dermatomyositis/polymyositis, and 
multiple sclerosis, as well as in autoim-
mune blistering skin diseases (Edwards 
and Cambridge, 2006; Kessel et al., 
2008; Sailler, 2008).
CD20 is a transmembrane glyco-
protein specifically expressed on B 
cells and regulated during differentia-
tion. It is first expressed on the cell sur-
face during the transition from pre-B to 
immature cell in the bone marrow, is 
maintained on mature naive, activated, 
and memory cells present in blood and 
in secondary lymphoid organs, and is 
lost upon plasma cell differentiation 
(Edwards and Cambridge, 2006; Kessel 
et al., 2008). Thus, rituximab treatment 
spares long-lived plasma cells that are 
resident in the bone marrow and repre-
sent the major source of serum antibod-
ies. Rituximab has proven remarkably 
potent in eradicating both malignant 
and normal B cells, because a single 
course usually leads to depletion of 
B cells from peripheral blood for 6–12 
months (Edwards and Cambridge, 2006; 
Kessel et al., 2008). In addition, there 
is evidence that the removal of B cells 
also occurs in secondary lymphoid 
tissues, although with slower kinetics 
(Edwards and Cambridge, 2006; Kessel 
et al., 2008; Yanaba et al., 2008).
The efficacy of rituximab is probably 
the result of a combination of factors: 
CD20 is expressed at high levels on 
B cells and does not become internal-
ized or shed from the plasma membrane 
following mAb treatment, allowing for 
prolonged persistence of the bound mAb 
on the cell surface. Different mechanisms 
have been implicated in rituximab-
mediated B-cell depletion, such as anti-
body-dependent cell-mediated cytotox-
icity (ADCC), complement-dependent 
cytotoxicity, and direct triggering of 
apoptosis (Glennie et al., 2007). The role 
of ADCC is supported by experiments in 
mouse models and by human data that 
indicate a correlation between FcgRIIIA 
polymorphisms and the extent of B-cell 
depletion by rituximab (Glennie et al., 
2007; Yanaba et al., 2008). In ADCC, 
the interaction between mAb Fc and 
FcgRs expressed on effector cells, such 
as natural killer cells, macro phages, or 
neutrophils, drives the killing of mAb-
coated target cells.
Pemphigus is a life-threatening auto-
immune blistering disorder of the skin 
and mucosae associated with autoAb 
directed against desmoglein (Dsg)-1 
and Dsg3, two transmembrane com-
ponents of desmosomes, which are 
cell–cell adhesion complexes (Stanley 
and Amagai, 2006). AutoAb produc-
tion in pemphigus is polyclonal, and 
the autoAb belong mainly to the IgG4 
and IgG1 subclasses. Two major forms 
of the disease—pemphigus vulgaris 
(PV) and pemphigus foliaceus (PF)—are 
distinguished. Ample data support the 
pathogenetic role of Dsg autoAb in PV 
and PF. Specific examples include the 
following: (i) serum levels of anti-Dsg1 
and anti-Dsg3 antibodies in patients 
generally correlate with disease activ-
ity, (ii) passive transfer of purified IgG 
from PV and PF sera in neonatal mice 
results in the induction of pemphigus-
like features, (iii) inactivation of the 
Dsg3 gene in mice results in a mucosal-
dominant PV-like phenotype, and (iv) 
immunization of Dsg3 knockout mice 
with murine Dsg3 and adoptive trans-
fer of the immune splenocytes into 
Rag2–/– immunodeficient mice result in 
persistent anti-Dsg3 autoAb production 
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and a PV-like disease phenotype. In 
vitro and in vivo findings also indi-
cate that autoreactive CD4+ T cells are 
involved in the pathogenesis of PV and 
PF, most likely by controlling the acti-
vation of specific B lymphocytes and 
possibly by inducing local inflamma-
tion (Hertl et al., 2006). Intriguingly, 
a subset of Dsg3-reactive T cells with 
regulatory functions has recently been 
identified, raising the possibility that 
this disease may be dependent on the 
fine balance between helper and sup-
pressor T cells.
In view of the key role played by 
autoAb in PV and PF, over the past few 
years rituximab has been used in cases 
of severe pemphigus resistant to con-
ventional immunosuppressive therapies 
and alternative therapeutic approaches, 
such as high-dose intravenous Ig. Four 
independent, nonrandomized, pro-
spective studies (Ahmed et al., 2006; 
Joly et al., 2007; Cianchini et al., 2007), 
including that by Eming et al. (2008, 
this issue) have been published to date. 
These studies demonstrate that ritux-
imab, in most cases administered in an 
adjuvant setting, led to complete remis-
sion in the large majority of PV and PF 
patients with refractory disease, with 
frequently sustained clinical benefits. 
In particular, a previous report (Joly et 
al., 2007) on the clinical outcomes of 
the patients analyzed by Mouquet et al. 
(2008, this issue) demonstrated that 18 
of 21 (86%) patients with severe PV or 
PF had complete remissions 3 months 
after a single cycle of four weekly 
infusions of rituximab, administered 
in association with cortico steroids in 
most of the patients (Joly et al., 2007). 
Disease relapse was observed in 9 of 
21 patients after a mean of 19 months, 
and, after a mean follow-up of 36 
months, 18 (86%) patients were free of 
disease, including 8 (38%) who were 
not receiving corticosteroids (Joly et al., 
2007; Mouquet et al., 2008). Eming et 
al. also describe a significant improve-
ment in all 11 PV patients treated with 
a single cycle of rituximab in associa-
tion with corticosteroids and immuno-
suppressive drugs.
Thus, the efficacy of rituximab in 
pemphigus is impressive. However, the 
mechanisms by which this is achieved 
are not well understood. The studies 
by Mouquet et al. and Eming et al. 
now provide further insight into this 
relevant issue. These authors confirm 
that in almost all treated pemphigus 
patients, complete CD19+ B-cell deple-
tion occurred, lasting up to 12 months. 
Furthermore, total serum IgG levels and 
the levels of antipneumococcal cap-
sular polysaccharide and tetanus tox-
oid antibodies remained unchanged, 
whereas only IgM levels decreased 
(Mouquet et al.). These findings are in 
line with published data obtained in 
both lymphoproliferative and autoim-
mune diseases (Looney et al., 2008). 
The observation that total serum IgG 
and protective antibody levels are not 
affected by a single course of rituximab 
is consistent with the fact that long-
lived plasma cells resident in bone mar-
row are CD20 negative and are there-
fore spared from the chimeric antibody. 
In contrast, both studies document a 
selective role of rituximab-induced 
B-cell depletion in decreasing autoAb 
levels. These findings imply that the 
pathogenetic antibodies are produced 
by an ongoing immune response that 
is continually fueled by specific B cells 
stimulated by antigen and possibly 
antigen-specific T cells. In particular, 
both groups demonstrate the following: 
(i) significantly decreased levels of anti-
Dsg autoAb in most treated patients 
undergoing clinical improvement and 
(ii) increasing titers of anti-Dsg antibod-
ies in relapsing patients. Again, these 
findings are in line with data in auto-
immune diseases such as rheumatoid 
arthritis, in which clinical improve-
ment and relapse correlate with the 
decrease and subsequent increase in 
autoAb levels in the majority of treat-
ed patients (Edwards and Cambridge, 
2006). The correlation between clini-
cal response and decreasing autoAb 
titers seems to be even more marked in 
diseases characterized by pathogenetic 
autoantibodies, such as idiopathic 
thrombotic thrombocytopenic purpura 
and acquired hemophilia (Barnett et 
al., 2008; Sadler, 2008).
Intriguingly, Mouquet et al. also 
highlight the fact that individual clinical 
responses following rituximab immu-
notherapy in pemphigus do not always 
correlate with changes in autoAb titers. 
The authors report that a minority of 
rituximab-treated PV patients in com-
plete remission had persistently high 
autoAb titers or showed a re-increase 
of anti-Dsg3 autoAb over time. In these 
patients, clinical remission might relate 
to a modification of targeted epitope 
profile. In fact, sera from PV patients 
in complete remission with persis-
tently high anti-Dsg3 levels no longer 
recognized the pathogenic N-terminal 
epitopes (EC1 and EC2) of Dgs3 that 
were targeted during the active phase of 
the disease. These data should be con-
firmed by further analyses, including the 
assessment of the autoAb pathogenicity 
in these patients. As for rituximab, its 
varying effect on autoAb levels in pem-
phigus could reflect the persistence of 
CD20 plasma cells with heterogeneous 
life spans, with short-lived plasma cells 
accounting for a significant proportion 
of the autoAb production.
With their long-term follow-up, 
Mouquet et al. clearly demonstrate that, 
in the majority of patients, autoAb pro-
duction remains at low levels well after 
B-lymphocyte recovery. It is interesting 
to note that, similar to what is described 
in rheumatoid arthritis, B cells that 
repopulate the peripheral blood after 
rituximab treatment are enriched in 
naive B cells (CD19+, CD27–), with 
their immature (CD5+, CD38high) phe-
notype, which has been considered an 
indicator of an origin in the recovering 
bone marrow (Edwards and Cambridge, 
2006). Another intriguing finding of 
Mouquet et al. is the disappearance of 
the oligoclonal peaks detected in some 
immunoglobulin IgM and IgG VH fami-
lies before treatment and the reconsti-
tution of a polyclonal profile following 
rituximab. This reconstituted polyclonal 
B-cell population could play a relevant 
role in the long-lasting remissions 
observed in a significant proportion of 
patients. It will be interesting to deter-
mine whether the memory phenotype 
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B cells that appear after rituximab 
retain all the specificities present before 
treatment, including reactivities against 
vaccines and common viruses.
Over the past few years, several 
studies have provided evidence that 
rituximab-induced B-cell depletion can 
be associated in different autoimmune 
diseases with modifications of the T-cell 
compartment, such as subset altera-
tions, changes in the activation state, 
and induction of cells with regulatory 
properties (Kessel et al., 2008; Liossis 
and Sfikakis, 2008). Immunophenotypic 
analyses of the T cells performed in both 
the study by Eming et al. and the one by 
Mouquet et al. indicate that rituximab in 
pemphigus does not significantly affect 
major T-cell subset numbers or pheno-
types. However, Eming et al. studied for 
the first time the frequency of circulat-
ing autoreactive Dsg3-specific CD4+ 
T helper (Th)-1 and Th2 cells using 
a magnetic activation cell-sorting 
cytokine secretion assay. They report a 
significant reduction in IFN-γ-secreting 
T cells (Th1) and Dsg3-specific IL-4-
secreting T cells (Th2). Such changes 
were already detectable 1 month follow-
ing rituximab administration, and they 
lasted for 12 and 6 months, respectively. 
In addition, the frequency of both Th1 
and Th2 cells remained low in patients 
with sustained CR, whereas it increased 
at 6 to 12 months in the three relapsing 
patients. Thus, Dsg3-specific Th1 and 
Th2 frequency decreases rapidly after 
rituximab and seems to parallel disease 
activity and autoAb levels. The effect on 
Dsg3-reactive CD4+ T cells appears, at 
least in part, to be specifically related to 
rituximab administration, because sys-
temic corticosteroids and immunosup-
pressive adjuvants had no significant 
effect on the overall frequency of Dsg3-
specific Th1 and Th2 cells. However, it 
cannot be excluded that the concomi-
tant use of rituximab and immunosup-
pressive treatments has a synergistic 
effect on humoral and cellular immune 
responses, including autoreactive CD4+ 
T cells, in treated patients.
The findings by Eming et al. (2008) 
are in agreement with those of a recent 
report demonstrating that B-cell deple-
tion by anti-CD20 inhibits autoreac-
tive T-cell activation in two animal 
models of autoimmune diseases: 
collagen-induced arthritis and type 1 
diabetes (Bouaziz et al., 2007). In par-
ticular, in collagen-induced arthritis, 
autoantigen-specific CD4+ T-cell prolif-
eration in response to autoantigen chal-
lenge was inhibited following B-cell 
depletion. Overall, Eming et al. indi-
cate that rituximab indirectly decreases 
the frequency of autoreactive CD4+ T 
cells via depletion of B cells as critical 
antigen-presenting cells. Although the 
crucial role of reciprocal T-cell–B-cell 
interactions in systemic autoimmune 
diseases is increasingly recognized 
(Shlomchik, 2008), almost no data 
are available regarding the function of 
autoreactive B cells as antigen-present-
ing cells for Dsg3-specific T cells in PV.
In conclusion, the studies of 
Mouquet et al. (2008) and Eming et al. 
(2008) give an overall picture of immu-
nodynamics following immunotherapy 
with rituximab in pemphigus and open 
new directions of investigations regard-
ing the mechanisms of action of this 
drug. This knowledge is relevant not 
only for a delineation of the optimal 
administration modalities for ritux-
imab and to guide the choice of novel 
therapeutic approaches in pemphigus 
but ultimately also for a better com-
prehension of disease pathogenesis. 
Overall, it is expected and anticipated 
that the increasing use of novel thera-
pies in autoimmune disorders—wheth-
er directly targeted B-cell therapies, 
including other biologicals targeting 
CD20 or CD22, or therapies indirectly 
modulating B cells, such as block-
ers of the B-cell survival factor BAFF/
BLyS—will greatly contribute to a better 
understanding of B-cell–T-cell interplay 
and thus of inflammatory and autoim-
mune disorders in general (Dörner and 
Burmester, 2008).
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